	US 12,188,945 B2
	Food-allergen specific antibody compositions
Scott A. Smith, White Bluff, TN (US)
Assigned to VANDERBILT UNIVERSITY, Nashville, TN (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on Oct. 30, 2023, as Appl. No. 18/497,432.
Application 18/497,432 is a continuation of application No. 17/127,953, filed on Dec. 18, 2020.
Application 17/127,953 is a continuation of application No. 16/481,165, granted, now 10,908,168, issued on Feb. 2, 2021, previously published as PCT/US2018/015870, filed on Jan. 30, 2018.
Claims priority of provisional application 62/452,603, filed on Jan. 31, 2017.
Prior Publication US 2024/0133895 A1, Apr. 25, 2024 Prior Publication US 2024/0230665 A9, Jul. 11, 2024
Int. Cl. A61K 39/395 (2006.01); A61K 39/35 (2006.01); A61K 45/06 (2006.01); C07K 16/16 (2006.01); C07K 16/18 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/686 (2013.01) [A61K 39/35 (2013.01); A61K 45/06 (2013.01); C07K 16/16 (2013.01); C07K 16/18 (2013.01); G01N 33/5308 (2013.01); C07K 2317/21 (2013.01); G01N 2333/43526 (2013.01); G01N 2333/43582 (2013.01)]

9 Claims

1. A pharmaceutical composition comprising:

a therapeutically effective amount of an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds a food allergen, wherein the food allergen is a peanut allergen and the antibody or the fragment thereof comprises heavy chain CDR1 SEQ ID NO: 105, heavy chain CDR2 SEQ ID NO: 106, heavy chain CDR3 SEQ ID NO: 107, light chain CDR1 SEQ ID NO: 183, light chain CDR2 of sequence KAS and light chain CDR3 SEQ ID NO: 185; and

a pharmaceutically acceptable carrier.